Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NanosonicsNNCSF 90 EV-to-EBITDA is 26.88 as of Jul. 14, 2026, which is 72% below its 10-year median of 96.56. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.52 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 511 Medical Devices & Instruments companies, Nanosonics ranks worse than 74.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nanosonics's enterprise value is $559.9 Mil.
Nanosonics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $20.8 Mil. Therefore, Nanosonics's EV-to-EBITDA for today is 26.88.
The historical rank and industry rank for Nanosonics's EV-to-EBITDA or its related term are showing as below:
NNCSF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 24.29 Med: 96.56 Max: 463.57
Current: 25.74
During the past 13 years, the highest EV-to-EBITDA of Nanosonics was 463.57. The lowest was 24.29. And the median was 96.56.
NNCSF's EV-to-EBITDA is ranked worse than 74.17% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs NNCSF: 25.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Nanosonics (OTCPK:NNCSF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanosonics's share price for today is $2.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanosonics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.044.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nanosonics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nanosonics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nanosonics's EV-to-EBITDA falls into.
Nanosonics's current Enterprise Value is $559.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanosonics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $20.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a EV-to-EBITDA of 26.88 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nanosonics. This is 72% below median its historical median of 96.56. Over the past decade, Nanosonics' EV-to-EBITDA has ranged from 24.29 to 463.57. According to the industry distribution chart, Nanosonics ranks #379 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 74.2%.
Is Nanosonics' EV-to-EBITDA too high?
Nanosonics' current EV-to-EBITDA of 26.88 is 72% below median its 10-year median of 96.56. Over the past 10 years, this metric has ranged from a low of 24.29 to a high of 463.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.20. Nanosonics' value of 26.88 is 89.3% above this industry median. Based on the distribution chart, Nanosonics ranks #379 out of 511 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #379 out of 511 companies for EV-to-EBITDA. This places Nanosonics in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. Nanosonics' value of 26.88 is 89.3% above this benchmark. Historically, Nanosonics' own EV-to-EBITDA has ranged from 24.29 to 463.57 over the past decade. While the company's 10-year median is 96.56 vs. the industry median of 14.20, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current EV-to-EBITDA of 26.88 is 89.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nanosonics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current EV-to-EBITDA is 26.88, which is 72% below median its own 10-year median of 96.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.52, compared to a current price of $2.55 — trading 27.6% below its estimated fair value. The current EV-to-EBITDA is 26.88, which is 72% below median its 10-year median of 96.56 and 89.3% above the Medical Devices & Instruments industry median of 14.20. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nanosonics (NNCSF), the current EV-to-EBITDA is 26.88 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 27.6% below its estimated GF Value™ of $3.52.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
EV-to-EBITDA: 26.88 (72% below median its 10-year median of 96.56)
GF Value™: $3.52 vs. price of $2.55 (27.6% below fair value)
Industry Position: 89.3% above the Medical Devices & Instruments median (#379 of 511)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
